Suzanne E. van Dijk

Suzanne E. van Dijk

Auto-generated profile, based on publicly available information

Suzanne E. van Dijk

Leiden University Medical Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
SDSuzanne E van Dijk
Suzanne E van Dijk
NDNadieh Drenth
Nadieh Drenth
AHAnne Hafkemeijer
Anne Hafkemeijer
GLGerda Labadie
Gerda Labadie
MWMarie-Noëlle W Witjes-Ané
Marie-Noëlle W Witjes-Ané
SRSanneke van Rooden
Sanneke van Rooden
Cerebral amyloid angiopathy (CAA) is frequently found post mortem in Alzheimer’s dementia, but often undetected during life especially since in vivo hallmarks of CAA and its vascular damage become overt relatively late in the disease process. Decreased neurovascular coupling to visual stimulation has been put forward as an early MRI marker for CAA disease severity. The current study investigates the role of neurovascular coupling in AD related dementia and its early stages. We included 25 subjective cognitive impairment, 33 mild cognitive impairment and 17 dementia patients and 44 controls. All participants underwent magnetic resonance imaging of the brain and neuropsychological assessment. Univariate general linear modeling analyses were used to assess neurovascular coupling between patient groups and controls. Moreover, linear regression analyses was used to assess the associations between neurovascular coupling and cognition. Our data show that BOLD amplitude is lower in dementia (mean 0.8 ± 0.2, p = 0.001) and MCI patients (mean 0.9 ± 0.3, p = 0.004) compared with controls (mean 1.1 ± 0.2). A low BOLD amplitude was associated with low scores in multiple cognitive domains. We conclude that cerebrovascular dysfunction, most likely due CAA, is an important comorbidity in early stages of dementia and has an independent effect on cognition.

1 June 2022 in Stroke
Verified
Journal Article
Open access
PDF file
SDSuzanne E. van Dijk
Suzanne E. van Dijk
JGJeroen van der Grond
Jeroen van der Grond
JLJessie Lak
Jessie Lak
ABAnnette van Den Berg-Huysmans
Annette van Den Berg-Huysmans
GLGerda Labadie
Gerda Labadie
SRSanneke van Rooden
Sanneke van Rooden
Background: Hemorrhagic and ischemic magnetic resonance imaging lesions as well as the more recently described decrease in vasomotor reactivity have been suggested as possible biomarkers for cerebral amyloid angiopathy (CAA). Analyses of these markers have been primarily cross-sectional during the symptomatic phase of the disease, with little data on their longitudinal progression, particularly in the presymptomatic phase of the disease when it may be most responsive to treatment. We used the unique opportunity provided by studying Dutch-type hereditary cerebral amyloid angiopathy (D-CAA) to determine longitudinal progression of CAA biomarkers during the presymptomatic as well as the symptomatic phase of the disease. Methods: In this longitudinal case-control study, magnetic resonance imaging markers and cognitive performance were assessed at baseline and after ≈4 years in 10 presymptomatic and 6 symptomatic D-CAA mutation carriers and 20 control subjects. These magnetic resonance imaging markers included hemorrhagic and ischemic manifestations, measurements of cerebral blood flow, and vasomotor reactivity to visual stimulation. Results: In presymptomatic D-CAA mutations carriers, vasomotor reactivity showed a decline over time for blood-oxygen-level–dependent amplitude ( P =0.011) and prolongation of time to peak ( P <0.001). In contrast, no significant changes in hemorrhagic markers, ischemic markers, cerebral blood flow, and cognition were found. In symptomatic D-CAA mutation carriers, the number of intracerebral hemorrhages increased over the 4-year period ( P =0.007). Conclusions: Our findings indicate that in the presymptomatic phase of D-CAA, cerebrovascular reactivity measured by the blood-oxygen-level–dependent amplitude and time to peak to visual stimulation progressively worsens and can thus be regarded as a disease progression marker. In the symptomatic phase, the most salient marker of progression appears to be recurrent intracerebral hemorrhage.

18 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
SDSuzanne E. van Dijk
Suzanne E. van Dijk
NDNadieh Drenth
Nadieh Drenth
AHAnne Hafkemeijer
Anne Hafkemeijer
GLGerda Labadie
Gerda Labadie
MWMarie‐Noëlle W. Witjes‐Ané
Marie‐Noëlle W. Witjes‐Ané
SRSanneke van Rooden
Sanneke van Rooden
Background: Neurovascular coupling is a fundamental aspect of brain function by regulating cerebral blood flow in response to regional neuronal activity. Increasing evidence suggest neurovascular decoupling occurs early in the progression of Alzheimer disease (AD), potentially reflecting early vascular damage. Therefore, understanding the relationship between neurovascular coupling and established vascular risk factors for AD is essential to gain deeper insights into the vascular mechanisms underlying AD. Methods: This cross‐sectional observational study investigated the association between neurovascular coupling and vascular risk factors for AD, specifically small vessel disease magnetic resonance imaging markers, cardiovascular risk factors, and the apolipoprotein E genotype. The cohort included 119 participants diagnosed with subjective cognitive impairment, mild cognitive impairment, and AD‐related dementia, as well as individuals without cognitive complaints. Neurovascular coupling was measured by blood‐oxygen‐level‐dependent functional magnetic resonance imaging amplitude in response to visual stimulation. Results: Our findings revealed that decreased neurovascular coupling is linked to structural brain changes typically seen in small vessel disease; specifically we found an association between neurovascular coupling and white matter hyperintensities load ( β =−0.199, P =0.030) and presence of lobar intracerebral hemorrhage ( β =−0.228, P =0.011). Conclusions: This raises the suggestion that a decreased neurovascular coupling in the disease process of AD is related to comorbid small vessel disease.

25 July 2022 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
SDSuzanne E. van Dijk
Suzanne E. van Dijk
JLJessie Lak
Jessie Lak
NDNadieh Drenth
Nadieh Drenth
AHAnne Hafkemeijer
Anne Hafkemeijer
SRSerge A.R.B. Rombouts
Serge A.R.B. Rombouts
SRSanneke van Rooden
Sanneke van Rooden
Background: Decreased cerebrovascular reactivity, measured as changes in blood‐oxygen‐level‐dependent (BOLD) signal, is a potential new cerebral amyloid angiopathy (CAA) severity marker. Before clinical application, the effect of aging on BOLD parameters, and reproducibility and test–retest reliability of these parameters should be assessed.Purpose: Assess the effect of healthy aging on cerebrovascular reactivity (BOLD amplitude, time to peak, and time to baseline). And determine reproducibility and test–retest reliability of these parameters.Study Type: Prospective‐observational.Population: Eighty‐six healthy adults (mean age 56 years, 55% female), 10 presymptomatic D‐CAA mutation carriers (mean age 34 years, 70% female), and 10 symptomatic D‐CAA mutation carriers (mean age 54 years, 70% female).Field Strength/Sequence: 3‐T, three‐dimensional (3D) T1‐weighted MRI and gradient echo BOLD fMRI.Assessment: To assess test–retest reliability of BOLD parameters, i.e. BOLD amplitude, time to peak, and time to baseline, BOLD fMRI scans were repeated three times immediately after each other, in both controls and mutation carriers. To assess reproducibility, BOLD fMRI scans were repeated with a 3‐week interval for each subject.Statistical Tests: Linear regression analyses and two‐way mixed absolute agreement intra‐class correlation approach.Results: Healthy aging was associated with decreased BOLD amplitude (β = −0.711) and prolonged time to baseline (β = 0.236) in the visual cortex after visual stimulation Reproducibility of BOLD amplitude was excellent (ICC 0.940) in the subgroup of healthy adults. Test–retest reliability for BOLD amplitude was excellent in healthy adults (ICC 0.856–0.910) and presymptomatic D‐CAA mutation carriers (ICC 0.959–0.981). In symptomatic D‐CAA mutation carriers, test–retest reliability was poor for all parameters (ICCs < 0.5).Data Conclusion: Healthy aging is associated with decreased cerebrovascular reactivity, measured by changes in BOLD response to visual stimulation. The BOLD amplitude appears to be a robust measurement in healthy adults and presymptomatic D‐CAA mutation carriers, but not in symptomatic D‐CAA mutation carriers.

13 March 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
SDSuzanne E. van Dijk
Suzanne E. van Dijk
NDNadieh Drenth
Nadieh Drenth
AHAnne Hafkemeijer
Anne Hafkemeijer
IDIsa Draaijer
Isa Draaijer
GLGerda Labadie
Gerda Labadie
SRSanneke van Rooden
Sanneke van Rooden
Background: Cognitive decline in Alzheimer's disease (AD) is increasingly linked to cerebrovascular dysfunction, including small vessel disease (SVD). Conventional SVD MRI markers primarily detect late-stage structural damage. Neurovascular coupling (NVC) has emerged as an early indicator of cerebrovascular function and is cross-sectionally associated with cognition, but its association with longitudinal decline remains unclear. Objective: To investigate whether baseline NVC is associated with cognitive decline over 3.5 years in individuals ranging from no cognitive complaints to memory clinic patients with subjective cognitive impairment (SCI) or mild cognitive impairment (MCI). Methods: Seventy-five participants underwent cognitive assessment and MRI, including BOLD fMRI during visual stimulation to assess NVC. Cognitive decline was analyzed as dichotomous outcome (stable versus decline; n = 75) using logistic regression and as continuous outcome for domain-specific change (z-score change; n = 69) using linear regression. Results: Lower baseline NVC was associated with global cognitive decline, both dichotomously (OR = 42.29, p = 0.017) and continuously (B = 0.45, p = 0.012). Baseline NVC was also associated with a decline in executive function (B = 0.47, p = 0.043), but not with other domain-specific decline. Among conventional SVD MRI markers, only lacunar infarcts were associated with decline (OR = 4.12, p = 0.037). Conclusions: Baseline NVC appears to be a predictor of global cognitive decline, outperforming most conventional SVD MRI markers. These findings support the potential utility of NVC as a prognostic marker of cognitive decline in early-stage AD, highlighting its promise for early intervention strategies targeting cerebrovascular dysfunction.

23 July 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
NDNadieh Drenth
Nadieh Drenth
SDSuzanne E. van Dijk
Suzanne E. van Dijk
AHAnne Hafkemeijer
Anne Hafkemeijer
SRSerge A.R.B. Rombouts
Serge A.R.B. Rombouts
JGJeroen van der Grond
Jeroen van der Grond
SRSanneke van Rooden
Sanneke van Rooden
Background: The mechanisms of early brain damage in cerebral amyloid angiopathy (CAA), a highly prevalent comorbid condition in Alzheimer's disease, are not completely understood. While current CAA diagnosis relies on late-stage MRI markers, impaired neurovascular coupling (NVC) has emerged as a promising early marker. Objective: To investigate whether early vascular changes in CAA are associated with functional brain consequences, we examined the association between NVC and various functional connectivity metrics. Methods: We analyzed MRI data from 93 older adults (71 ± 9 years old). A subgroup meeting Boston criteria v2.0 for possible or probable CAA ( n = 46) was analyzed separately to investigate associations in confirmed CAA-related pathology. NVC (time to peak, time to baseline, and BOLD amplitude) was assessed in the occipital cortex using a visual stimulation task. Functional connectivity was assessed at multiple scales using resting-state fMRI, including within ten standard networks, between individual brain regions (edgewise analysis), and across the whole brain (graph theory). Results: General linear models, adjusted for age, sex, and clinical diagnosis, showed no significant associations between NVC and global connectivity metrics (networks and graph theory). Edgewise analyses revealed limited significant localized functional connections for each NVC measure. Findings were consistent across the total sample and the CAA subgroup. Conclusions: Early CAA-related pathology is associated with localized rather than global functional connectivity. While large-scale connectivity remains preserved, edgewise analyses indicate subtle localized functional alterations. This suggests that functional connectivity disruption may originate as small-scale deficits that only progress into widespread, global impairment in advanced disease stages.